Achieve Life Sciences (ACHV) Short term Debt (2016 - 2026)

Achieve Life Sciences' (ACHV) quarterly Short term Debt came in at $1.6 million in Q4 2025, up 7.9% on a QoQ basis from $1.4 million in Q3 2025.

Achieve Life Sciences (ACHV) Short term Debt (2016 - 2026) Analysis & Trends

Achieve Life Sciences (ACHV) has 6 years of Short term Debt data on file, last reported at $1.6 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, changed N/A from the prior year.
Short term Debt grew to $1.6 million in Q4 2025, from $1.4 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $17.1 million in Q1 2024 to a low of $528000.0 in Q4 2023.
A 4-year average of $7.1 million and a median of $1.6 million in 2025 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2023 — Short term Debt slumped 96.71% — and 2024, when it grew 4.7%.
Tracing ACHV's Short term Debt over 4 years: stood at $16.1 million in 2022, then tumbled by 96.71% to $528000.0 in 2023, then surged by 1567.42% to $8.8 million in 2024, then slumped by 82.31% to $1.6 million in 2025.
The last three Short term Debt figures came in at $1.6 million (Q4 2025), $1.4 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Achieve Life Sciences	330.88 Mn	330.88 Mn	-

Download Data